2024
Hepatorenal Syndrome Type 1: Diagnosis and Treatment
Belcher J. Hepatorenal Syndrome Type 1: Diagnosis and Treatment. Advances In Kidney Disease And Health 2024, 31: 100-110. PMID: 38649214, DOI: 10.1053/j.akdh.2023.05.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeKidney injuryFunctional acute kidney injuryUrinary biomarkers of kidney injuryAssociated with significant morbidityFractional excretion of sodiumNeutrophil gelatinase-associated lipocalinDiagnostic criteriaBiomarkers of kidney injuryMultiple urinary biomarkersOptimal dosing strategiesExcretion of sodiumPoint-of-care ultrasoundAccurate differential diagnosisAnalog of vasopressinSets of diagnostic criteriaAdvanced cirrhosisAlbumin administrationSignificant morbidityVolume resuscitationTherapeutic optionsDosing strategiesFractional excretionDifferential diagnosis
2021
Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS, Investigators H. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. American Journal Of Kidney Diseases 2021, 79: 737-745. PMID: 34606933, DOI: 10.1053/j.ajkd.2021.08.016.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeRespiratory adverse eventsPrimary end pointFirst-line therapyMean arterial pressureSympathetic nervous systemSynthetic vasopressin analogueAdvanced cirrhosisHRS reversalAldosterone systemKidney injuryLack of evidenceAdverse eventsMortality benefitPortal pressureArterial pressureFulminant formSplanchnic systemSignificant morbidityRenal vasculatureVasodilatory substancesApparent increased rateTerlipressinCONFIRM trials